Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J75/00—Processes for the preparation of steroids in general
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
  • C07J1/0051—Estrane derivatives
  • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
  • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
  • C07J1/0051—Estrane derivatives
  • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/30—Oestrogens
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
  • C07J1/0051—Estrane derivatives
  • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
  • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention relates to a new process for the synthesis of a key intermediate in the synthesis of Estetrol.
• Estrogenic substances are commonly used in methods of Hormone Replacement Therapy (HRT) and methods of female contraception.
• Estetrol is a biogenic estrogen that is endogenously produced by the fetal liver during human pregnancy. Recently, estetrol has been found effective as an estrogenic substance for use in HRT.
• Other important applications of estetrol are in the fields of contraception, therapy of auto-immune diseases, prevention and therapy of breast and colon tumors, enhancement of libido, skin care, and wound healing.
• 3-A-oxy-estra 1 ,3,5(10),15-tetraen-17-ol is prepared in 6 steps from estrone where A is a benzyl group, the steps comprising protection of the 3-OH group by a benzyl group, then transformation of the 17-keto-group to a 17,17-ethylenedioxy derivative which is halogenated at the Ci 6 position using pyridinium bromide perbromide.
• Dehydrohalogenation is carried out by using potassium terbutoxyde in dimethylsulfoxide.
• Deprotection of the 17-keto-group is conducted using p- toluene-sulfonic acid monohydrate in aqueous acetone. Reduction of 17-keto-group affords the 17-ol derivative.
• a process for the preparation of a compound of formula (I) (3-P 1 -oxy-estra-1 ,3,5(10),15-tetraene-17-ol ) is provided:
• said process comprises the steps of :
• the present invention encompasses a process for the preparation of a compound of formula (I), said process comprising the steps of
• the invention provides an improved process for producing 3-P 1 -oxy-estra-1 , 3, 5(10), 15- tetraene-17-ol of formula (I) in significantly higher yield and/or at lower cost than possible by the previous known syntheses.
• the present invention also encompasses a process for the preparation of estetrol, said process comprising preparing a compound of formula (I) by a process according to the first aspect of the invention and further reacting compound of formula (I) to produce estetrol.
• the present invention also encompasses estetrol directly obtained by the process according to the second aspect of the invention, for use in a method selected from a method of hormone replacement therapy, a method of treating vaginal dryness, a method of contraception, a method of enhancing libido, of method of treating skin, a method of promoting wound healing, and a method of treating or preventing a disorder selected from the group consisting of autoimmune diseases, breast tumors and colorectal tumors.
• alkyl by itself or as part of another substituent, refers to a straight or branched saturated hydrocarbon group joined by single carbon-carbon bonds having 1 to 6 carbon atoms, for example 1 to 5 carbon atoms, for example 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms.
• the subscript refers to the number of carbon atoms that the named group may contain.
• Ci -6 alkyl means an alkyl of one to six carbon atoms.
• alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, ie f-butyl, 2-methylbutyl, pentyl iso-amyl and its isomers, hexyl and its isomers.
• C 3 - 6 cycloalkyl refers to a saturated cyclic alkyl radical containing from about 3 to about 6 carbon atoms.
• Examples of monocyclic C 3-6 cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
• C 2 - 6 alkenyl by itself or as part of another substituent, refers to an unsaturated hydrocarbyl group, which may be linear, or branched, comprising one or more carbon- carbon double bonds.
• Examples of C 2-6 alkenyl groups are ethenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl and its isomers, 2-hexenyl and its isomers, 2,4-pentadienyl and the like.
• C 6 -ioaryl by itself or as part of another substituent, refers to a polyunsaturated, aromatic hydrocarbyl group having a single ring (i.e.
• C 6- ioaryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated herein.
• Non- limiting examples of C 6- ioaryl comprise phenyl, naphthyl, indanyl, or 1 ,2,3,4-tetrahydro- naphthyl.
• C 6 -ioarylCi- 6 alkyl by itself or as part of another substituent, refers to a Ci -6 alkyl group as defined herein, wherein one or more hydrogen atoms are replaced by one or more C 6- ioaryl as defined herein.
• aralkyl radicals include benzyl, phenethyl, dibenzylmethyl, methylphenylmethyl, 3-(2-naphthyl)-butyl, and the like.
• C 1-6 alkylcarbonyl represents a group of Formula -C0-R 3 , wherein R a is Ci -6 alkyl as defined herein.
• C 3-6 cycloalkylcarbonyr' represents a group of Formula -CO-R c , wherein R a is C 3 - 6 cycloalkyl as defined herein.
• C 2 - 6 alkenylCi- 6 alkanoate refers to a compound having the Formula R b -0-CO-R a wherein R a is Ci -6 alkyl as defined herein and R b is C 2-6 alkenyl as defined herein.
• C 2 - 6 alkenylC 3 - 6 cycloalkanoate refers to a compound having the Formula R b -0-CO-R c wherein R c is C 3 - 6 cycloalkyl as defined herein and R b is C 2-6 alkenyl as defined herein.
• C 1-6 alkylenecarbonate refers to a compound having the Formula R b -0-CO-0-R a wherein R a is Ci -6 alkyl as defined herein and R b is C 2-6 alkenyl as defined herein.
• the present invention relates to a process for preparing 3-P 1 -oxy-estra-1 ,3,5(10), 15- tetraene-17-ol of formula (I), wherein P 1 is a protecting group selected from R 1 CO-, R 2 Si-R 3 R 4 ; wherein R 1 is a group selected from Ci -6 alkyl or C 3-6 cycloalkyl, each group being optionally substituted by 1 , 2 or 3 substituents independently selected from fluoro or Ci -4 alkyl; preferably R 1 is selected from the group comprising methyl, ethyl, propyl, isopropyl, butyl, isobutyl, ie f-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each group being optionally substituted by 1 , 2 or 3 substituents independently selected from fluoro or Ci -4 alkyl; more preferably R 1 is methyl, ethy
• R 2 , R 3 and R 4 are each independently a group selected from Ci -6 alkyl or phenyl, said Ci -6 alkyl or phenyl, being optionally substituted with 1 , 2 or 3 substituents independently selected from fluoro or Ci -6 alkyl; preferably R 2 , R 3 and R 4 are each independently selected from the group comprising methyl, ethyl, propyl, isopropyl, butyl, isobutyl, ie f-butyl, and phenyl, each group being optionally substituted with 1 , 2 or 3 substituents each independently selected from fluoro or Ci -4 alkyl; preferably R 2 , R 3 and R 4 are each independently selected from the group comprising methyl, ethyl, propyl, isopropyl, or tert- butyl, and phenyl, each group being optionally substituted with 1 , 2 or 3 substituents each independently selected from fluoro or Ci -2 alkyl,
• said process comprises the steps of
• compound of formula (I) is subsequently converted into another compound by routine processes applicable for conversion of functional groups,
• P 1 is R 1 CO-; preferably P 1 is a group selected from Ci -4 alkylcarbonyl or C 4-6 cycloalkylcarbonyl, each group being optionally substituted by 1 , 2 or 3 substituents independently selected from fluoro or Ci -4 alkyl; more preferably P 1 is a group selected from Ci -2 alkylcarbony or C 5-6 cycloalkylcarbonyl, each group being optionally substituted by 1 , 2 or 3 substituents independently selected from fluoro or Ci -2 alkyl; for example P 1 is selected from acetyl, or cyclohexylcarbonyl, preferably P 1 is acetyl.
• P 2 is R 1 CO-; preferably P 2 is a group selected from Ci -4 alkylcarbonyl or C 4-6 cycloalkylcarbonyl, each group being optionally substituted by 1 , 2 or 3 substituents independently selected from fluoro or Ci -4 alkyl; more preferably P 2 is a group selected from Ci -2 alkylcarbony or C 5-6 cycloalkylcarbonyl, each group being optionally substituted by 1 , 2 or 3 substituents independently selected from fluoro or Ci -4 alkyl; for example P 2 is selected from acetyl, or cyclohexylcarbonyl, preferably P 2 is acetyl.
• P 1 and P 2 are each independently R 1 CO-.
• P 1 is R 2" Si-R 3 R 4 .
• P 1 is selected from the group comprising fe/f-butyl-dimethyl-silyl, diphenyl-methyl-silyl, dimethyl-phenyl-silyl, trimethyl-silyl, triethyl- silyl and triisopropyl-silyl, each group being optionally substituted by one or more substituents independently selected from fluoro or Ci -4 alkyl; more preferably P 1 is tert- butyl-dimethyl-silyl.
• step (a) comprises the steps of (a1 ) protecting the hydroxyl of compound of formula (II) with a silylating agent to produce a compound of formula (lla), wherein P 1 is R 2" Si-R 3 R 4 ; and
• P 2 is R 2" Si-R 3 R 4 ; preferably P 2 is selected from the group comprising ie f-butyl-dimethyl-silyl, diphenyl-methyl-silyl, dimethyl-phenyl-silyl, trimethyl-silyl, triethyl- silyl and triisopropyl-silyl, each group being optionally substituted by one or more substituents independently selected from fluoro or Ci -4 alkyl, more preferably P 2 is ie f- butyl-dimethyl-silyl.
• P 1 and P 2 are each independently R 2" Si-R 3 R 4 .
• P 1 is R 2" Si-R 3 R 4 ; and P 2 is R 1 CO-.
• P 1 is selected from the group comprising ie f-butyl-dimethyl-silyl, diphenyl-methyl-silyl, dimethyl-phenyl-silyl, trimethyl-silyl, triethyl-silyl or triisopropyl-silyl, each group being optionally substituted by one or more substituents independently selected from fluoro or Ci -4 alkyl; more preferably P 1 is ie f-butyl-dimethyl-silyl; and preferably P 2 is a group selected from Ci -6 alkylcarbonyl or C 3-6 cycloalkylcarbonyl, each group being optionally substituted by 1 , 2 or 3 substituents independently selected from fluoro or Ci -4 alkyl; preferably P 2 is a group selected from Ci -4 alkylcarbonyl or C 5-6 cycloalkylcarbony
• the silylating agent can be selected from the group comprising Ci -6 alkylsilylchloride, Ci -6 alkylsilyltriflate, phenylsilylchloride, phenylsilyltriflate, Ci -6 alkylphenylsilylchloride, Ci -6 alkylphenylsilyltriflate, each group being optionally substituted by one or more substituents independently selected from fluoro or Ci -4 alkyl.
• the process for the preparation of 3-P 1 -estra 1 , 3, 5(10), 15-tetraene- 17-ol of formula (I) from estrone of formula (I I) can be preformed in 3 steps as shown in Scheme 1 .
• the compound of formula (I) can then be further reacted to prepare estetrol.
• estrone is reacted with an acylating agent.
• said acylating agent is C2- 6 alkenylCi -6 alkanoate or C 2 - 6 alkenylC 3 - 6 cycloalkanoate.
• the acylating agent is selected from the group comprising C 2-6 alkenylpropanoate, C 2-6 alkenylbutanoate, C 2-6 alkenylpentanoate, C 2-6 alkenylhexanoate, C 2-6 alkenylcyclopropanoate, C 2-6 alkenylcyclobutanoate, C 2-6 alkenylcyclopentanoate, and C 2-6 alkenylcyclohexanoate.
• the acylating agent is selected from the group comprising isopropenyl acetate, isopropenyl propionate, isopropenyl butyrate, isopropenyl isobutyrate, vinyl acetate, vinyl propionate, prop-2-enyl cyclohexanecarboxylate, ethenyl cyclopentanecarboxylate, and vinyl cyclohexanoate. More preferably, the acylating agent is selected from the group comprising isopropenyl acetate, isopropenyl propionate, isopropenyl butyrate, isopropenyl isobutyrate, vinyl acetate, and vinyl propionate.
• the acylation can be performed in the presence of an acid, such as in the presence of sulfuric acid, or in the presence of a C 6- ioarylsulfonic acid, optionally substituted by one or more chloro substituents.
• an acid such as in the presence of sulfuric acid, or in the presence of a C 6- ioarylsulfonic acid, optionally substituted by one or more chloro substituents.
• suitable acid include para-toluene sulfonic acid, and sulfuric acid.
• estrone of formula (II) can be was reacted with isopropenyl acetate in the presence of sulfuric acid or para-toluene sulfonic acid to give the estra-1 ,3,5 (10), 16- tetraene-3,17-diol, 3,17-diacetate.
• the reaction can be performed under reflux, optionally under inert atmosphere, such as nitrogen atmosphere.
• the product can be used as such in the next step or further purified by known techniques in the art such as by chromatography, for example on silica with a suitable eluant such as methylene chloride/hexane or ethyl acetate/hexane.
• estrone of formula (II) is reacted with a silylating agent.
• the silylating agent can be selected from the group comprising Ci -6 alkylsilyl triflate, phenylsilyltriflate, Ci -6 alkylphenylsilyltriflate, Ci -6 alkylsilylchloride, Ci-phenylsilylchloride, Ci -6 alkylphenylsilylchloride, each group being optionally substituted by one or more substituents independently selected from fluoro or Ci -4 alkyl.
• formation of protected estrone silyl ether can be performed by reaction of a silylating agent such as ie f-butyl dimethylsilyltriflate, diphenylmethylsilyltriflate, dimethylphenylsilyltriflate, trimethylsilyltriflate, triethylsilyltriflate, or triisopropylsilyltriflate.
• a silylating agent such as ie f-butyl dimethylsilyltriflate, diphenylmethylsilyltriflate, dimethylphenylsilyltriflate, trimethylsilyltriflate, triethylsilyltriflate, or triisopropylsilyltriflate.
• the reaction can be performed in the presence of a suitable base such as imidazole, 2,6- lutidine, collidine, triethylamine, or 1 ,8-diazabicyclo[5.4.0]undec-7-ene
• the reaction can be performed in the presence of a suitable solvent such as dichloromethane, toluene or dimethylformamide or a mixture thereof.
• a suitable solvent such as dichloromethane, toluene or dimethylformamide or a mixture thereof.
• the formation of protected estrone silyl ether can also be performed by reaction of a silylating agent such as ie f-butyl dimethylsilylchloride, diphenylmethylsilylchloride, dimethylphenylsilylchloride, trimethylsilylchloride, triethylsilylchloride or triisopropylsilylchloride in the presence of a suitable base such as lithium diisopropylamide (LDA), tert-butyl lithium, sodium or potassium bis(trimethylsilyl)amide (NaHMDS, KHMDS) or lithium tetramethylpiperidine.
• LDA lithium diisopropylamide
• NaHMDS
• Step (b) of the present process comprises reacting the compound of formula (III) in the presence of palladium acetate or a derivative thereof such as palladium chloride or Tris(dibenzylideneacetone)dipalladium (Pd 2 (dba) 3 ), preferably palladium acetate or palladium chloride, more preferably palladium acetate to produce a compound of formula (IV).
• palladium acetate or a derivative thereof such as palladium chloride or Tris(dibenzylideneacetone)dipalladium (Pd 2 (dba) 3 ), preferably palladium acetate or palladium chloride, more preferably palladium acetate to produce a compound of formula (IV).
• said palladium acetate or a derivative thereof can be present in stoichiometric amounts, or sub-stoichiometric catalytic amounts.
• step (b) can be performed using stoichiometric amounts of palladium acetate, palladium chloride or Tris(dibenzylideneacetone)dipalladium, preferably stoichiometric amounts of palladium acetate, preferably in a suitable solvent such acetonitrile, benzonitrile or dimethylsulfoxide, preferably benzonitrile.
• This reaction can be performed at room temperature.
• said step (b) can be performed using sub-stoichiometric catalytic amounts of palladium acetate, palladium chloride, or Tris(dibenzylideneacetone)dipalladium, preferably sub-stoichiometric catalytic amounts of palladium acetate, in the presence of a Ci -6 alkylene carbonate such as allyl carbonate and in the presence of an organotin compound as catalyst.
• the organotin compound is tri-butyltin methoxide.
• the Ci -6 alkylene carbonate is allyl methyl carbonate.
• the reaction can be performed under reflux conditions, optionally under inert atmosphere such as nitrogen or argon atmosphere.
• said step (b) can be performed using sub-stoichiometric catalytic amounts of palladium acetate under an oxygen atmosphere. In another example, said step (b) can be performed using sub-stoichiometric catalytic amounts of palladium chloride, under an oxygen atmosphere. In another example, said step (b) can be performed using sub-stoichiometric catalytic amounts of
• said oxygen atmosphere is pure molecular oxygen or atmospheric oxygen (air or circulating air, or renewable air).
• the amount of palladium acetate, palladium chloride or Tris(dibenzylideneacetone)dipalladium is at most 0.50 equivalents, preferably at most 0.40 equivalents, more preferably at most 0.30 equivalents, yet more preferably at most 0.2 equivalents, yet more preferably at most 0.10 equivalents, yet more preferably at most 0.05 equivalents, yet more preferably at most 0.03 equivalents per equivalent of compound of formula (III).
• step (b) is performed with at most 0.10 equivalents of palladium acetate, preferably at most 0.05 equivalents, preferably at most 0.03 equivalents per equivalent of compound of formula (III), in the presence of pure molecular oxygen or atmospheric oxygen.
• the next step in the process comprises the reduction of the compound of formula (IV) with a reducing agent to produce compound of formula (I).
• said reducing agent is a metal hydride compound.
• the metal hydride compound can be selected from the group comprising LiAIH 4 , NaBH 4 , NaBH(OAc) 3 , ZnBH 4 , and NaBH 4 /CeCI 3 .
• said reducing agent is NaBH 4 /CeCI 3 .
• said reduction can be performed in a suitable solvent or a mixture thereof, such as in tetrahydrofuran, or a mixture of methanol and tetrahydrofuran.
• the reaction can be performed at low temperatures such as below 15°C, for example below 10°C.
• compound of formula (IV) is not isolated but directly reduced to the alcohol using said reducing agent.
• step (b) and (c) are performed in one pot.
• This one-pot/two-step procedure is the shortest chemical pathway described to obtain compound of formula (I).
• This process offers the advantages that the 17-hydroxy function of the compound of formula (I) could be also protected by a protecting group such as an acyl group, more preferably an acetyl group which could be removed in the same time that the 3-protecting group such as 3-acetyl, preferably 3-acetoxy group offering a never described synthesis of estetrol in 6 steps.
• the 17-hydroxy function of the compound of formula (I) could be also protected by a silyl group, which could be removed in the same time that the 3-silyl protecting group offering a never described synthesis of estetrol in 6 steps.
• step (a) can be performed in two steps and comprises the steps of (a1 ) protecting the hydroxyl of compound of formula (II) using a silylating agent to produce a compound of formula (I la), wherein P 1 R 2" Si-R 3 R 4 ; and
• estrone of formula (II) is reacted with a silylating agent to produce compound of formula (I la).
• the silylating agent can be selected from the group comprising Ci -6 alkylsilyl chloride, phenylsilyl chloride, Ci -6 alkylphenylsilyl chloride; each group being optionally substituted by one or more substituents independently selected from fluoro or Ci -4 alkyl.
• formation of protected estrone silyl ether can be performed by reaction of a silylating agent such as ie f-butyl dimethylsilylchloride, diphenylmethylsilylchloride, dimethylphenylsilylchloride, trimethylsilylchloride, triethylsilylchloride, or triisopropylsilylchloride.
• a silylating agent such as ie f-butyl dimethylsilylchloride, diphenylmethylsilylchloride, dimethylphenylsilylchloride, trimethylsilylchloride, triethylsilylchloride, or triisopropylsilylchloride.
• the reaction can be performed in the presence of a base such as imidazole, 2,6-lutidine, collidine, triethylamine, or 1 ,8-diazabicyclo[5.4.0]undec-7-ene (D
• the next step comprises, converting the ketone of compound of formula (I la) in the presence of an acylating agent to produce a compound of formula (II) wherein P 2 is acyl (compound of formula (Ilia)).
• acylating agents and conditions are as described herein above.
• the next step in the process of scheme 2 comprises reacting the compound of formula (Ilia) in the presence of palladium acetate or a derivative thereof such as palladium chloride or Tris(dibenzylideneacetone)dipalladium (Pd 2 (dba) 3 ) to produce compound of formula (IV) wherein P 1 is R 2" Si-R 3 R 4 (compound of formula (IVa)).
• This reaction can be performed as described herein above.
• the next step in the process comprises the reduction of the compound of formula (IVa) with a reducing agent to produce compound of formula (I) wherein P 1 is R 2" Si-R 3 R 4 (compound of formula (la)).
• This reaction can be performed as described herein above.
• the processes according to the present invention have the advantage that the protective group can be removed in situ at the end of the synthesis by conventional methods such as removal of silyl protecting group with fluoride ions, such as tetra-n-butylammonium fluoride; as described in Coppola, G.M. Org Prep Proced, 2007, 39 (2),199-292 hereby incorporated by reference; or removal of silyl protecting groups using 2,3-dichloro-5,6- dicyano-p-benzoquinone as described in Tanemura, K. J Chem Soc, Perkin Trans 1 1992, (22), 2997-2998; hereby incorporated by reference.
• fluoride ions such as tetra-n-butylammonium fluoride
• the present process has the advantage that 3-P 1 -oxy-estra1 ,3,5(10),15-tetraen-17-ol of formula (I), and subsequently estetrol, can be obtained from estrone in a reduced number of steps compared to prior art processes, which is more convenient for an economical and industrial synthesis.
• the present invention also encompasses a process for the preparation of estetrol, said process comprising preparing a compound of formula (I) using the process of the invention and further reacting compound of formula (I) to produce estetrol.
• the present invention also encompasses the use of estetrol directly obtained by the process the invention for the manufacture of a pharmaceutical composition, preferably for use in a method selected from a method of hormone replacement therapy, a method of treating vaginal dryness, a method of contraception, a method of enhancing libido, of method of treating skin, a method of promoting wound healing, and a method of treating or preventing a disorder selected from the group consisting of autoimmune diseases, breast tumors and colorectal tumors.
• Example 1 Preparation of a compound of formula (I) wherein P 1 is acetyl according to an embodiment of the invention.
• Step 1 Estra-1 , 3, 5 (10), 16-tetraene-3, 17-diol, 3, 17 -di acetate
• Step 2 3-acetoxy-estra-1 , 3, 5 (10), 15-tetraen-17-one
• Example 2 Preparation of a compound of formula (I) wherein P 1 is t-butyldimethylsilyl according to an embodiment of the invention.
• Step 1 3,17-di-t-butyldimethylsiloxy-estra-1 , 3, 5(10)-16-tetraene-17-ol
• Step 2 3-t-butyldimethylsiloxy-estra-1 , 3, 5 (10)-15-tetraene-17-one
• Step 3 3 -t-butyldimethylsiloxy-estra-1 , 3, 5 (10)-15-tetraene-17-ol
• Example 3 Preparation of a compound of formula (I) wherein P 1 is t-butyldimethylsilyl according to an embodiment of the invention.
• Step 1 3 -t-butyldimethylsiloxy-estra-1 , 3, 5(10) -triene-17-one
• estrone 100g, 0.37 mole
• imidazole 50.36g, 0.74 mole
• t-butyl-dimethylsilyl chloride 61.3g, 0.41 mole
• Step 3 3 -t-butyldimethylsiloxy-estra-1 , 3, 5 (10)-15-tetraene-17-one
• the product was collected by filtration. It weighted 91 g (85% yield) and was used in the next step without further purification.
• Step 4 3 -t-butyldimethylsiloxy-estra-1 , 3, 5 (10)-15-tetraene-17-ol
• the reduction step was performed as described in step 3 of example 2: the collected material was dissolved in THF and a solution of cerium chloride heptahydrate (1 eq) in methanol was added. The mixture was cooled to 0°C sodium borohydride (1 .5eq) was added portion wise keeping the temperature below 9°C. At this end of the addition the mixture was stored for one hour then quenched by addition of a 2N HCI solution. The solution was partly evaporated in situ and water was added. The precipitate was collected by filtration and dried. After crystallization from a mixture of ethanol /diisopropyl ether the product was collected by filtration and dried.
• Step 2 of Example 1 was repeated using different reagent and reactions conditions as listed in Table 1 .
• 3-acetoxy-estra-1 , 3, 5 (10), 15-tetraen-17-one was obtained.
• the yields and conversion rates are given in Table 1.
• THF tetrahydrofuran
• ACN acetonitrile RT: room temperature
• DMSO dimethylsulfoxide
• Step 2 of Example 2 was repeated using different reagent and reactions conditions as listed in Table 2. 3-t-butyldimethylsiloxy-estra-1 , 3, 5 (10)-15-tetraene-17-one was obtained. The yields and conversion rates are given in Table 2.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Endocrinology (AREA)
• Engineering & Computer Science (AREA)
• Diabetes (AREA)
• Epidemiology (AREA)
• Steroid Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (21)

Applications Claiming Priority (4)

Publications (1)

Family

ID=45003353

Family Applications (1)

Country Status (24)

Cited By (9)

Families Citing this family (12)

Citations (2)

Family Cites Families (67)

• 2012
  • 2012-06-01 PT PT127290542T patent/PT2714710T/pt unknown
  • 2012-06-01 EP EP12729054.2A patent/EP2714710B1/en active Active
  • 2012-06-01 KR KR1020137031483A patent/KR101994805B1/ko active Active
  • 2012-06-01 CN CN201710354709.5A patent/CN107266514A/zh active Pending
  • 2012-06-01 CN CN201280026162.1A patent/CN103703014A/zh active Pending
  • 2012-06-01 RS RS20160478A patent/RS54880B1/sr unknown
  • 2012-06-01 US US14/122,872 patent/US11053274B2/en active Active
  • 2012-06-01 SG SG2013086681A patent/SG195118A1/en unknown
  • 2012-06-01 HU HUE12729054A patent/HUE029252T2/en unknown
  • 2012-06-01 SI SI201230598A patent/SI2714710T1/sl unknown
  • 2012-06-01 ME MEP-2016-130A patent/ME02454B/me unknown
  • 2012-06-01 JP JP2014513214A patent/JP6425540B2/ja active Active
  • 2012-06-01 MX MX2013014045A patent/MX341561B/es active IP Right Grant
  • 2012-06-01 AU AU2012264602A patent/AU2012264602B2/en active Active
  • 2012-06-01 PL PL12729054T patent/PL2714710T3/pl unknown
  • 2012-06-01 HR HRP20160692TT patent/HRP20160692T2/hr unknown
  • 2012-06-01 DK DK12729054.2T patent/DK2714710T3/en active
  • 2012-06-01 ES ES12729054.2T patent/ES2579175T3/es active Active
  • 2012-06-01 CA CA2835981A patent/CA2835981C/en active Active
  • 2012-06-01 EA EA201301316A patent/EA023991B1/ru unknown
  • 2012-06-01 WO PCT/EP2012/060447 patent/WO2012164096A1/en not_active Ceased
  • 2012-06-01 BR BR112013030830A patent/BR112013030830B1/pt active IP Right Grant
• 2013
  • 2013-11-11 ZA ZA2013/08446A patent/ZA201308446B/en unknown
• 2016
  • 2016-06-15 CY CY20161100525T patent/CY1118150T1/el unknown
  • 2016-06-30 SM SM201600206T patent/SMT201600206B/it unknown
• 2017
  • 2017-08-10 JP JP2017155801A patent/JP6479912B2/ja active Active

Patent Citations (2)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events